The FDA has granted Orphan Drug Designation to BioInvent International AB's BOVNF BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL).
- BioInvent is a collaborating partner of CASI Pharmaceuticals Inc CASI.
- BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials.
- One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have relapsed or are refractory to rituximab.
- A second Phase 1/2 trial is investigating BI-1206 in combination with Merck & Co Inc MRK anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.
- Price Action: CASI shares are up 4.21% at $0.72 during the premarket session on the last check Thursday.
Loading...
Loading...
BOVNFBioInvent International AB
$0.1870-94.3%
Edge Rankings
Momentum
N/A
Growth
N/A
Quality
N/A
Value
N/A
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.